| 2026-01-21 | -12.0% | analyst | Yahoo Finance | Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It? - Yahoo Finance |
| 2026-01-22 | -11.6% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2026-01-22 | -11.6% | news | Yahoo Finance | Why Abbott Laboratories (ABT) Shares Are Sliding Today - Yahoo Finance |
| 2026-01-22 | -11.6% | earnings | Yahoo Finance | Abbott Laboratories (NYSE:ABT) Misses Q4 CY2025 Revenue Estimates, Stock Drops - Yahoo Finance |
| 2026-01-22 | -11.6% | executive | Investor's Business Daily | Abbott Tumbles On Disappointing Fourth Quarter As Exact Closing Looms - Investor's Business Daily |
| 2022-10-19 | -7.8% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2023-07-20 | +7.2% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2025-07-17 | -6.7% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2025-07-17 | -6.7% | news | Yahoo Finance | Why Abbott Laboratories (ABT) Shares Are Plunging Today - Yahoo Finance |
| 2026-04-15 | -6.6% | earnings | Seeking Alpha | Abbott seen posting modest Q1 earnings amid Nutrition segment slowdown |
| 2023-04-19 | +6.5% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2026-04-16 | -6.1% | earnings | Seeking Alpha | Abbott stock slips on guidance cut, ranks 10th in healthcare equipment Quant ratings |
| 2026-04-16 | -6.1% | earnings | Seeking Alpha | Abbott forecasts 6.5%-7.5% 2026 comparable sales growth while integrating Exact Sciences with $0.20 EPS dilution |
| 2026-04-16 | -6.1% | earnings | Seeking Alpha | Abbott Laboratories (ABT) Q1 2026 Earnings Call Transcript |
| 2026-04-16 | -6.1% | news | Seeking Alpha | Abbott Laboratories: This Dividend Growth King Has Rarely Been So Cheap |
| 2026-04-16 | -6.1% | earnings | Seeking Alpha | Health Care ETFs take notice as Abbott Laboratories slides on earnings |
| 2026-04-16 | -6.1% | news | Seeking Alpha | Biggest stock movers Thursday: AEHR, ABT, HOOD, COIN, and more |
| 2026-04-16 | -6.1% | earnings | Seeking Alpha | Abbott Laboratories in charts: Medical Devices continues to see Y/Y double-digit growth momentum in Q1; nutrition falls |
| 2026-04-16 | -6.1% | M&A | Seeking Alpha | Abbott hits 52-week low as Exact Sciences buyout hurts outlook (update) |
| 2026-04-16 | -6.1% | earnings | Seeking Alpha | Earnings Snapshot: Abbott Laboratories tops Q1 revenue estimates; lowers FY26 Adj. profit outlook |
| 2026-04-16 | -6.1% | earnings | Seeking Alpha | Abbott Laboratories Non-GAAP EPS of $1.15 in-line, revenue of $11.16B beats by $160M |
| 2026-04-16 | -6.1% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2026-04-16 | -6.1% | news | The Motley Fool | Why Abbott Laboratories Stock Tumbled on Thursday - The Motley Fool |
| 2026-04-16 | -6.1% | earnings | Barron's | Abbott Earnings Beat Estimates. That Might Have Been the Only Good News for the Stock. - Barron's |
| 2026-04-16 | -6.1% | news | simplywall.st | Is Abbott Laboratories (ABT) Now Offering Value After A 20% Share Price Slide? - simplywall.st |
| 2025-04-16 | +5.9% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2023-10-18 | +5.8% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2025-12-12 | +5.4% | legal | SEC EDGAR | ABT 8-K: 5.02, 5.03 (SEC Filing) |
| 2026-04-21 | -4.8% | news | Seeking Alpha | Abbott Laboratories Just Got Interesting: Dividend Yield Near 3% Signals Opportunity |
| 2026-04-21 | -4.8% | news | Seeking Alpha | Abbott Laboratories: Buy The Dip On This Dividend King |
| 2026-04-21 | -4.8% | news | Trefis | Abbott Laboratories Stock Hands $28 Bil Back – Worth a Look? - Trefis |
| 2026-04-21 | -4.8% | news | Seeking Alpha | Abbott Laboratories: Buy The Dip On This Dividend King (NYSE:ABT) - Seeking Alpha |
| 2026-04-21 | -4.8% | news | Seeking Alpha | Abbott Laboratories Just Got Interesting: Dividend Yield Near 3% Signals Opportunity - Seeking Alpha |
| 2026-04-21 | -4.8% | news | Trefis | Abbott Laboratories Stock Hands $28 Bil Back - Worth a Look? - Trefis |
| 2026-04-21 | -4.8% | news | TradingView | Is the Options Market Predicting a Spike in Abbott Laboratories Stock? - TradingView |
| 2026-04-21 | -4.8% | earnings | MarketBeat | Ticino Wealth Buys Shares of 11,005 Abbott Laboratories $ABT - MarketBeat |
| 2026-04-21 | -4.8% | analyst | 24/7 Wall St. | Wall Street Refuses to Blink: 2 Healthcare Stocks at 52-Week Lows That Analysts Still Love - 24/7 Wall St. |
| 2026-04-21 | -4.8% | news | TradingKey | Abbott Laboratories Stock (ABT) Moved Down by 3.33% on Apr 21: Key Drivers Unveiled - TradingKey |
| 2025-01-22 | +4.4% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2022-04-20 | +4.4% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2021-10-20 | +4.1% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2025-10-15 | -4.0% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2025-10-15 | -4.0% | news | Yahoo Finance | Why Abbott Laboratories (ABT) Stock Is Down Today - Yahoo Finance |
| 2026-04-09 | -3.7% | news | Seeking Alpha | Abbott Laboratories: A Dividend Aristocrat With A Compelling Valuation And Return Potential |
| 2026-04-09 | -3.7% | earnings | Yahoo Finance | Abbott (ABT) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance |
| 2026-04-09 | -3.7% | news | Seeking Alpha | Abbott Laboratories: A Dividend Aristocrat With A Compelling Valuation And Return Potential - Seeking Alpha |
| 2026-01-29 | +3.6% | news | TIKR.com | Down 16% In Last 12 Months, Will Abbott Laboratories Stock Recover In 2027? - TIKR.com |
| 2025-11-12 | +3.4% | earnings | Yahoo Finance | Here’s Why Abbott Laboratories (ABT) Traded Down in Q3 - Yahoo Finance |
| 2026-04-20 | -3.4% | earnings | Quiver Quantitative | Abbott Laboratories Stock (ABT) Opinions on Q1 Earnings and Guidance Cut - Quiver Quantitative |
| 2026-04-20 | -3.4% | news | The Motley Fool | Better Medical Device Stock Right Now: Abbott Laboratories vs. Dexcom - The Motley Fool |
| 2026-04-20 | -3.4% | news | 24/7 Wall St. | Has the Abbott Laboratories Sell-Off Finally Created an Entry Point? - 24/7 Wall St. |
| 2026-02-20 | +3.1% | news | Seeking Alpha | Abbott Laboratories declares $0.63 dividend |
| 2026-02-20 | +3.1% | news | TIKR.com | Abbott Laboratories Stock Is Down 16% From Its 52-Week High. Here’s Where the Stock Could Go in 2026 - TIKR.com |
| 2026-01-30 | +2.9% | news | Yahoo Finance | Decent Organic Sales Growth Expected for Abbott Laboratories (ABT) in 2026 - Yahoo Finance |
| 2024-11-15 | +2.9% | legal | SEC EDGAR | ABT 8-K: 5.02 (SEC Filing) |
| 2026-01-27 | -2.9% | earnings | Yahoo Finance | Optimism around Abbott Laboratories (NYSE:ABT) delivering new earnings growth may be shrinking as stock declines 11% this past week - Yahoo Finance |
| 2026-04-10 | -2.9% | news | Seeking Alpha | Dividend Roundup: AGNC Investments, Abbott Labs, AbbVie, and more |
| 2026-04-10 | -2.9% | news | Seeking Alpha | Chicago jury orders Abbott to pay $53M in preterm infant formula trial |
| 2026-04-10 | -2.9% | news | Yahoo Finance | Is Abbott Laboratories (ABT) Appealing After Recent Share Price Pullback? - Yahoo Finance |
| 2026-04-10 | -2.9% | news | Investing.com | Abbott Laboratories stock hits 52-week low at $100.85 - Investing.com |
| 2024-04-17 | -2.8% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2025-12-08 | -2.7% | news | Yahoo Finance | Here's Why Abbott (ABT) Fell More Than Broader Market - Yahoo Finance |
| 2026-02-10 | +2.6% | news | TIKR.com | After a 15% Drop, Is Abbott Stock Set Up for a Comeback in 2026? - TIKR.com |
| 2021-12-10 | +2.5% | legal | SEC EDGAR | ABT 8-K: 5.02, 5.03 (SEC Filing) |
| 2025-11-24 | -2.5% | news | Yahoo Finance | Is Weakness In Abbott Laboratories (NYSE:ABT) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Yahoo Finance |
| 2023-01-25 | -2.4% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2026-02-26 | +2.4% | earnings | Seeking Alpha | Abbott's Meltdown Is Worth Buying, Compelling, Profitable Growth Prospects |
| 2026-02-26 | +2.4% | legal | SEC EDGAR | ABT 8-K: 1.01 and (SEC Filing) |
| 2026-02-26 | +2.4% | earnings | Seeking Alpha | Abbott's Meltdown Is Worth Buying, Compelling, Profitable Growth Prospects - Seeking Alpha |
| 2026-02-23 | +2.4% | news | Seeking Alpha | Abbott eyes $20B bond sale to fund purchase of Exact Sciences - report |
| 2026-02-23 | +2.4% | M&A | Quiver Quantitative | Abbott Laboratories Stock (ABT) Opinions on Exact Sciences Acquisition - Quiver Quantitative |
| 2026-02-23 | +2.4% | news | Yahoo Finance | Is Abbott Laboratories (ABT) Pricing Reflect Long Term Value After Recent Share Price Weakness - Yahoo Finance |
| 2026-03-04 | -2.4% | news | Yahoo Finance | Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance |
| 2026-04-08 | -2.3% | earnings | MarketBeat | Abbott Laboratories (NYSE:ABT) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat |
| 2026-04-08 | -2.3% | earnings | MarketBeat | The Goldman Sachs Group Issues Pessimistic Forecast for Abbott Laboratories (NYSE:ABT) Stock Price - MarketBeat |
| 2025-11-20 | +2.1% | legal | SEC EDGAR | ABT 8-K: 1.01, 7.01, 8.01 (SEC Filing) |
| 2025-11-11 | +2.0% | analyst | Yahoo Finance | Citi Reaffirms Buy Rating on Abbott (ABT) Following Favorable Court Ruling - Yahoo Finance |
| 2026-03-23 | -2.0% | legal | SEC EDGAR | ABT 8-K: 8.01 and (SEC Filing) |
| 2024-01-24 | -2.0% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2026-03-10 | -1.8% | news | Yahoo Finance | Is Abbott Laboratories (ABT) Pricing Reflect Its Mixed Share Performance And Growth Prospects? - Yahoo Finance |
| 2026-01-28 | -1.8% | analyst | Yahoo Finance | How New Price Targets Are Shaping The Evolving Story For Abbott Laboratories (ABT) - Yahoo Finance |
| 2026-01-28 | -1.8% | earnings | Yahoo Finance | 5 Insightful Analyst Questions From Abbott Laboratories’s Q4 Earnings Call - Yahoo Finance |
| 2026-02-04 | +1.8% | legal | Seeking Alpha | Abbott glucose monitor sensor recall classified as most serious by FDA |
| 2026-02-04 | +1.8% | analyst | Yahoo Finance | Do Wall Street Analysts Like Abbott Laboratories Stock? - Yahoo Finance |
| 2026-03-22 | -1.6% | news | Yahoo Finance | Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness - Yahoo Finance |
| 2026-03-21 | -1.6% | news | Yahoo Finance | Is Abbott Laboratories (ABT) A Good Stock To Buy Now? - Yahoo Finance |
| 2022-01-26 | -1.6% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2026-03-18 | -1.5% | news | Yahoo Finance | Is Trending Stock Abbott Laboratories (ABT) a Buy Now? - Yahoo Finance |
| 2026-03-02 | -1.5% | news | Yahoo Finance | Abbott (ABT) Stock Sinks As Market Gains: Here's Why - Yahoo Finance |
| 2026-04-06 | -1.5% | earnings | MarketBeat | Abbott Laboratories $ABT Shares Acquired by BXM Wealth LLC - MarketBeat |
| 2023-06-12 | -1.4% | legal | SEC EDGAR | ABT 8-K: 5.02 (SEC Filing) |
| 2026-04-07 | -1.4% | earnings | MarketBeat | A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain? - MarketBeat |
| 2026-04-07 | -1.4% | news | Yahoo Finance | Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness - Yahoo Finance |
| 2021-09-01 | +1.3% | legal | SEC EDGAR | ABT 8-K: 5.02, 5.03 (SEC Filing) |
| 2026-01-12 | -1.2% | news | Yahoo Finance | Abbott (ABT) Stock Sinks As Market Gains: Here's Why - Yahoo Finance |
| 2026-02-25 | +1.2% | news | Yahoo Finance | Is Abbott Laboratories Stock Underperforming the Nasdaq? - Yahoo Finance |
| 2024-10-16 | +1.1% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2025-12-23 | -1.1% | news | Yahoo Finance | Is Abbott Laboratories Attractively Priced After Recent Share Price Gains And DCF Concerns? - Yahoo Finance |
| 2024-07-18 | -1.1% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2026-04-23 | -1.0% | news | Barchart | This Boring Dividend King Might Be the Safest Pick to Add to Your Portfolio |
| 2026-04-23 | -1.0% | earnings | Zacks | Is Innovation-Led Growth Driving ISRG's Revenues Above Procedures? |
| 2026-04-23 | -1.0% | news | GlobeNewswire | Catheters Market Report 2025-2030, Profiles and Strategy Analysis of Leading Players - Abbott Laboratories, Boston Scientific, Medtronic, Terumo, and B. Braun |
| 2026-04-23 | -1.0% | news | GlobeNewswire | Global Automated Insulin Delivery System Market Size/Share Worth USD 2684 Million by 2035 at a 10.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis) |
| 2026-01-13 | +1.0% | news | Yahoo Finance | Abbott Laboratories (NYSE:ABT) is favoured by institutional owners who hold 80% of the company - Yahoo Finance |
| 2026-01-13 | +1.0% | news | Yahoo Finance | Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance |
| 2026-01-13 | +1.0% | M&A | Yahoo Finance | Why Abbott Laboratories (ABT) Story Is Shifting With Exact Sciences Deal Talk And Legal Wins - Yahoo Finance |
| 2022-07-20 | -1.0% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2025-08-26 | -1.0% | news | Yahoo Finance | Is Abbott Laboratories' (NYSE:ABT) Stock's Recent Performance A Reflection Of Its Financial Health? - Yahoo Finance |
| 2026-04-22 | -0.9% | legal | Trefis | How ISRG Just Secured The U.S. Market |
| 2026-04-22 | -0.9% | news | GlobeNewswire | IoT Medical Devices Market Research and Global Forecast Report 2026-2036: Shift Toward Connected Healthcare Delivery and Rapid Expansion of Remote Patient Monitoring Driving Opportunities |
| 2026-04-22 | -0.9% | news | Yahoo Finance | Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance |
| 2026-04-22 | -0.9% | earnings | MarketBeat | KLP Kapitalforvaltning AS Cuts Stake in Abbott Laboratories $ABT - MarketBeat |
| 2026-04-22 | -0.9% | earnings | MarketBeat | Moran Wealth Management LLC Sells 73,546 Shares of Abbott Laboratories $ABT - MarketBeat |
| 2026-03-19 | -0.8% | news | The Motley Fool | 1 Magnificent Dividend Stock Down 22% That's a Screaming Buy Right Now - The Motley Fool |
| 2026-03-14 | +0.8% | analyst | Trefis | Why RMD Could Outperform Abbott Laboratories Stock - Trefis |
| 2026-01-24 | +0.7% | news | Yahoo Finance | Is Abbott’s January Pullback a Good Time to Buy? - Yahoo Finance |
| 2026-03-03 | -0.7% | news | Trefis | Better Value & Growth: STE, RMD Lead Abbott Laboratories Stock - Trefis |
| 2025-12-31 | -0.7% | news | Yahoo Finance | Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock - Yahoo Finance |
| 2026-02-12 | +0.7% | news | The Motley Fool | Abbott Labs: The Healthcare Dividend Stock I'd Happily Hold Forever - The Motley Fool |
| 2024-05-01 | -0.7% | legal | SEC EDGAR | ABT 8-K: 5.02 (SEC Filing) |
| 2026-04-01 | -0.6% | earnings | Seeking Alpha | Abbott: A Brighter Investment Case Heading Into Q1 Earnings (Rating Upgrade) |
| 2026-04-01 | -0.6% | news | Yahoo Finance | Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock - Yahoo Finance |
| 2026-04-02 | -0.6% | news | Stock Titan | Director at Abbott (NYSE: ABT) receives stock equivalent unit award - Stock Titan |
| 2026-04-02 | -0.6% | news | Stock Titan | Abbott Laboratories (ABT) director receives 382 stock equivalent units as fees - Stock Titan |
| 2026-04-02 | -0.6% | news | Stock Titan | Abbott (ABT) director Gonzalez receives 321 stock equivalent units as fees - Stock Titan |
| 2026-04-02 | -0.6% | news | Stock Titan | Abbott (ABT) director Robert Alpern awarded 76 stock equivalent units as fees - Stock Titan |
| 2026-04-19 | -0.6% | news | simplywall.st | Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness - simplywall.st |
| 2026-04-18 | -0.6% | earnings | Seeking Alpha | Earnings Scoreboard: 85% of S&P 500 early reporters beat EPS estimates as Y/Y growth hits 25 firms |
| 2025-05-01 | -0.6% | legal | SEC EDGAR | ABT 8-K: 5.02 (SEC Filing) |
| 2022-09-15 | +0.6% | legal | SEC EDGAR | ABT 8-K: 5.02, 5.03 (SEC Filing) |
| 2024-01-29 | +0.6% | legal | SEC EDGAR | ABT 8-K: 1.01, 1.02and2.03 (SEC Filing) |
| 2026-04-11 | -0.6% | news | Seeking Alpha | Abbott ordered to pay $70M in damages in Chicago baby formula case |
| 2026-02-06 | -0.6% | M&A | Seeking Alpha | Exact Sciences ticks higher amid reports HSR for Abbott deal expired |
| 2026-02-06 | -0.6% | executive | thestreet.com | Abbott Labs CEO makes $2M bet as stock sinks - thestreet.com |
| 2025-11-26 | -0.6% | news | Yahoo Finance | Is Abbott Laboratories Stock Underperforming the S&P 500? - Yahoo Finance |
| 2026-02-15 | -0.5% | news | Yahoo Finance | Could The Market Be Wrong About Abbott Laboratories (NYSE:ABT) Given Its Attractive Financial Prospects? - Yahoo Finance |
| 2021-12-13 | +0.5% | legal | SEC EDGAR | ABT 8-K: 5.02 (SEC Filing) |
| 2026-04-17 | -0.5% | legal | SEC EDGAR | ABT 8-K: 8.01 and (SEC Filing) |
| 2026-04-17 | -0.5% | earnings | MarketBeat | Abbott Stock Crash: Rebound Could Be Coming Fast - MarketBeat |
| 2026-04-17 | -0.5% | news | Trefis | Abbott Laboratories vs Medtronic: Which Stock Could Rally? - Trefis |
| 2026-04-17 | -0.5% | news | Trefis | Why Is Abbott Stock Trending Lower? - Trefis |
| 2026-04-17 | -0.5% | earnings | TIKR.com | Abbott Laboratories Stock Tumbles 6% On Weak Q2 Earnings Guidance - TIKR.com |
| 2026-04-17 | -0.5% | earnings | TipRanks | Abbott Labs Stock (ABT) Hit with Slew of Downgrades After Earnings - TipRanks |
| 2022-10-21 | -0.4% | legal | SEC EDGAR | ABT 8-K: 5.02 (SEC Filing) |
| 2026-01-23 | -0.4% | analyst | Investing.com | Abbott Labs stock price target lowered to $125 by Bernstein SocGen - Investing.com |
| 2026-01-23 | -0.4% | earnings | Yahoo Finance | Assessing Abbott Laboratories (ABT) Valuation After Q4 2025 Earnings Miss And Softer 2026 Guidance - Yahoo Finance |
| 2026-01-23 | -0.4% | analyst | Investing.com | UBS reiterates Buy rating on Abbott Labs stock with $158 price target - Investing.com |
| 2026-01-23 | -0.4% | earnings | Investing.com | TD Cowen lowers Abbott Labs stock price target on Q4 revenue miss - Investing.com |
| 2026-01-31 | -0.4% | news | Seeking Alpha | Insider trades: JNJ, Intel, IBM among notable names |
| 2021-07-22 | +0.3% | legal | SEC EDGAR | ABT 8-K: 2.02 and (SEC Filing) |
| 2026-02-08 | -0.3% | analyst | Yahoo Finance | Abbott Laboratories (ABT): Short-Term Headwinds, Strategic Pipeline Strength, and UBS Buy Rating - Yahoo Finance |
| 2026-02-07 | -0.3% | news | Seeking Alpha | Insider trades: Merck, Intel, Micron among notable names |
| 2026-03-24 | -0.2% | news | Yahoo Finance | Is It Time To Reconsider Abbott Laboratories (ABT) After Recent Share Price Weakness? - Yahoo Finance |
| 2026-03-24 | -0.2% | news | Yahoo Finance | Abbott (ABT) Stock Rated Buy on Strong Diabetes Trial Results - Yahoo Finance |
| 2026-03-09 | +0.2% | news | Seeking Alpha | Abbott Laboratories Offers Long-Term Upside Despite Recent Stumbles |
| 2026-03-09 | +0.2% | legal | SEC EDGAR | ABT 8-K: 1.01, 2.03 (SEC Filing) |
| 2026-03-09 | +0.2% | news | Seeking Alpha | Abbott Laboratories Offers Long-Term Upside Despite Recent Stumbles (NYSE:ABT) - Seeking Alpha |
| 2026-01-16 | +0.2% | news | Yahoo Finance | Is Abbott Laboratories (ABT) Price Weakness Creating A Potential Opportunity Now? - Yahoo Finance |
| 2025-10-07 | +0.2% | earnings | Yahoo Finance | Abbott Laboratories (ABT): A Healthcare Leader Powering the List of Profitable Dividend Stocks - Yahoo Finance |
| 2025-09-01 | -0.2% | news | Yahoo Finance | How Is Abbott Laboratories' Stock Performance Compared to Other Medical Devices Stocks? - Yahoo Finance |
| 2025-12-27 | +0.1% | news | Yahoo Finance | Is Weakness In Abbott Laboratories (NYSE:ABT) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Yahoo Finance |
| 2026-01-26 | -0.1% | news | Seeking Alpha | Abbott Laboratories snaps six straight sessions of losses |
| 2026-01-26 | -0.1% | news | Yahoo Finance | Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance |
| 2026-02-02 | +0.1% | news | Seeking Alpha | Abbott: Long-Term Investment Opportunity For Dividend Growth Investors |
| 2026-03-12 | +0.1% | analyst | Yahoo Finance | How The Story On Abbott Laboratories (ABT) Is Shifting As Analysts Rework Targets And Risks - Yahoo Finance |
| 2026-03-12 | +0.1% | earnings | Yahoo Finance | Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks - Yahoo Finance |
| 2026-04-26 | — | earnings | MarketBeat | Concurrent Investment Advisors LLC Purchases 17,137 Shares of Abbott Laboratories $ABT - MarketBeat |
| 2026-04-25 | — | news | PR Newswire | Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026 |
| 2026-04-25 | — | news | Simply Wall St. | A Look At Abbott Laboratories ABT Valuation After New Cancerguard Early Cancer Detection Data |
| 2026-04-25 | — | earnings | TIKR.com | Abbott Laboratories Q1 2026 Earnings: $2B CGM Quarter, 65% Upside Priced In - TIKR.com |
| 2026-04-25 | — | news | simplywall.st | Is There Now An Opportunity In Abbott Laboratories (ABT) After Recent Share Price Pullback? - simplywall.st |
| 2026-04-24 | — | analyst | Insider Monkey | Daiwa Downgrades Abbott Laboratories (ABT), Sees Limited Upside |
| 2026-04-24 | — | news | Zacks | Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet |
| 2026-04-24 | — | news | Seeking Alpha | Abbott Laboratories: Buying A Healthcare Giant On Sale |
| 2026-04-24 | — | news | Seeking Alpha | Abbott Laboratories: Buying A Healthcare Giant On Sale (NYSE:ABT) - Seeking Alpha |
| 2026-04-24 | — | news | ChartMill | ABT Stock Price, Quote & Chart | ABBOTT LABORATORIES (NYSE:ABT) - ChartMill |